Safety Study of Passive Immunization for Patients With Mild to Moderate Alzheimer's Disease
Status:
Unknown status
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
This research study will assess whether AAB-001 is safe, well tolerated and effective for use
in patients with Alzheimer's Disease. AAB-001 is a new drug that is not available outside
this study. AAB-001 is an antibody (a type of protein usually produced by white blood cells
to destroy other substances in the body). In Alzheimer's disease a protein called amyloid
gathers in the brain and is thought to cause symptoms like memory loss and confusion. It is
hoped that AAB-001 will attach to the amyloid protein in your brain and help your body to
remove it.